ORIGINAL CONTRIBUTION - CLINICS IN PEDIATRIC NEUROLOGY |
|
Year : 2017 | Volume
: 3
| Issue : 4 | Page : 180-183 |
|
Assessment of serum lipid profile and liver function parameters in children with epilepsy on phenytoin or valproic acid monotherapy for 6 months and beyond
Muzamil M Mugloo1, Rubeena Akhtar2, Seema Malik3
1 Department of Neonatology, Kanchi Kamakoti Childs Trust Hospital, Chennai, Tamil Nadu, India 2 Department of Anesthesia and Intensive Care, Sabah Hospital, Kuwait 3 Department of Pediatrics, Vidal Health Care Hospitals, Chennai, Tamil Nadu, India
Correspondence Address:
Muzamil M Mugloo Department of Neonatology, Kanchi Kamakoti Childs Trust Hospital, Chennai, Tamil Nadu India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/astrocyte.astrocyte_13_17
|
|
Objectives: The highest incidence of epilepsy in children coupled with the need of long-term antiepileptic treatment could lead to development of metabolic complications at an early age. Phenytoin and valproic acid are commonly used antiepileptic drugs in children. This study aimed to assess the serum lipid profile and liver function tests in children with epilepsy on phenytoin or valproic acid monotherapy for 6 months and beyond. Materials and Methods: This prospective descriptive study recruited children from the pediatric outpatient department of a tertiary care GB Pant Children Hospital, Srinagar, Kashmir, India from August 2009 to September 2011. All consecutive children diagnosed with epilepsy as per International League Against Epilepsy definition aged 3–18 years on phenytoin or valproic acid monotherapy for 6 months or beyond were enrolled. After baseline clinical and anthropometric evaluation (including body mass index [BMI]), the fasting blood samples were analyzed for serum lipid profile and liver enzyme changes. Results: Total of 75 children were enrolled. There were 25 patients each in phenytoin, valproic acid, and control group. We observed statistically significant high mean total cholesterol and alkaline phosphatase levels in group receiving phenytoin when compared with valproic acid or control group. Conclusion: The lipid and liver enzyme abnormalities may be observed in children on phenytoin or valproic acid therapy, which warrants careful screening and monitoring. |
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|